Lead Product(s) : AEVI-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
Details : CERC-002 is a first-in-class anti-LIGHT monoclonal antibody. LIGHT is homologous to lymphotoxin and exhibits an inducible expression. It competes with the HSV glycoprotein D for binding to the herpesvirus entry mediator, a receptor expressed on T lymphoc...
Product Name : CERC-002
Product Type : Antibody
Upfront Cash : Undisclosed
March 29, 2021
Lead Product(s) : AEVI-002
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Cerecor
Deal Size : Undisclosed
Deal Type : Licensing Agreement